New Treatments Activated in Clinical Trial at Henry Ford Cancer Institute

In a global clinical trial, GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), Henry Ford Cancer Institute is the first to activate two new treatments for glioblastoma. The GBM AGILE trial allows for global collaboration and has the potential to increase breakthroughs in the research and treatment for glioblastoma. This trial will eventually enroll patients at 35 sites in the United States, Canada, Europe, and China.

The two treatments tested in this trial are VAL-083 from Kintara Therapeutics, Inc.  and paxalisib from Kazia Therapeutics Limited. Both interventions are being tested in newly-diagnosed and recurrent glioblastoma.

Learn more about this innovative trial here.

Like this article?

Facebook
Twitter
Email

Recommended Reads for Caregivers & Loved ones: “Daughter” by Laura Dill

My First Time Attending SNO (Society for Neuro-Oncology)!

CaringBridge: Bridging the Gap Between Patients and Caregivers

Explore Topics

tbd

Find Resources

tbd

Join Your Path to Hope

tbd

Get the Latest from Brains for the Cure

Add your address to our mailing list to get monthly updates about progress in the fight against brain tumors, as well as new community opportunities.

Leave a comment

Brains for the Cure is a program of the Head for the Cure Foundation, which is powered by the generous support of donors. Learn more about how you can join the fight.